Lifeward makes robotic exoskeletons and anti-gravity rehabilitation systems for people with mobility impairments. The core product is the ReWalk Personal Exoskeleton, a wearable, battery-powered robotic suit that enables people with spinal cord injury (paraplegia) to stand, walk, and navigate stairs. The device is sized to the individual and intended for daily home and community use. The second major product line is AlterG, acquired in 2023, which uses patented differential air pressure technology to reduce gravitational load so patients can walk or run at a fraction of their normal body weight — enabling rehabilitation from lower extremity injuries with less pain. AlterG systems are installed in over 6,000 facilities globally across rehab clinics, hospitals, and sports programs. Lifeward sells ReWalk primarily to individuals with spinal cord injury, with reimbursement coming from Medicare, the VA, workers' compensation, and private insurers. AlterG is sold as capital equipment directly to clinical and sports facilities, with recurring revenue from proprietary consumable shorts and service contracts. The U.S. is the largest market, with Germany the most developed international market. ReWalk sales depend heavily on payor reimbursement approvals, a slow, documentation-intensive process. Medicare set a fee schedule of $91,032 per ReWalk unit in April 2024, which has driven consecutive quarterly growth in U.S. placements. Lifeward sells direct in the U.S. and Germany, and through over 40 distributors internationally.